Vehicle-treated NASH mice showed significant up-regulation in CCR2 mRNA expression levels (3.5 ± 1.7) compared with the vehicle-treated normal mice. This evidence concerns the gene CCR2 and metabolic dysfunction-associated steatohepatitis.